Tag Archives: (SAGE)

When Good Earnings Can’t Hide The Ugly Truth

You know that feeling when your favorite restaurant starts serving smaller portions but jacks up the price? That’s Biogen (BIIB) right now. Sure, they beat Q2 earnings estimates like a drum, pulling in $2.65 billion in revenue against a $2.32 billion consensus, but scratch beneath that shiny surface and you’ll find the same old story […]